Obermatt
See Similar Stocks →

Cogent Biosciences

NSQ:COGT · US19240Q2012
BiotechnologySmall

360° View

54
Price/Sales41
Price/Earnings84
Price/Book9
Dividend Yield—
Revenue Growth91
Profit Growth8
Capital Growth55
TSR 52w92
Leverage15
Liquidity31
Refinancing49
Combined48
Analyst Opinions19
Pro Holdings97
Opinion Changes50
Market Pulse72

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Employees251
Websitecogentbio.com
ISINUS19240Q2012
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesHematologyOncologyGeneticsBiotechnologyHealth CareMedicalTherapeutics

Description

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. The company's most advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine ki…

Analysis

Cogent Biosciences's 360° View rank of 54 places it above its peer average — better than 54% of its true peers.

It's growing solidly (54) and reasonably valued (74). On safety it is highly leveraged (13), and the market shows favorable sentiment (71). Taken together, its Combined rank of 48 reads as below its peer average.

360° rank · history

1007550250
54
2026

All-time high

54

Jun 2026

All-time low

17

Mar 2026

Average rank

36

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
41
—
—
—
Price/Earnings
84
—
—
—
Price/Book
9
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
74
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cogent Biosciences with its peers
Eledon Pharmaceuticals
NAQ:ELDN
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Jade Biosciences
NAQ:JBIO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Taysha Gene Therapies
NSQ:TSHA
21
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Revolution Medicines
NSQ:RVMD
32
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Dyne Therapeutics
NSQ:DYN
34
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sionna Therapeutics
NMQ:SION
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →